GCM
KYMR icon

Graham Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Graham Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,557
Closed -$304K – 1211
2024
Q1 		$304K Sell
7,557
-6,237
-45% -$223K 0.01% 781
2023
Q4 		$351K Buy
+13,794
New +$247K 0.01% 683
2023
Q3 		– Sell
-25,840
Closed -$594K – 1169
2023
Q2 		$594K Buy
+25,840
New +$740K 0.02% 506
2022
Q4 		– Sell
-101,001
Closed -$2.2M – 1184
2022
Q3 		$2.2M Buy
101,001
+70,238
+228% +$1.85M 0.09% 200
2022
Q2 		$605K Buy
30,763
+17,611
+134% +$411K 0.02% 607
2022
Q1 		$556K Buy
+13,152
New +$555K 0.02% 517

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Graham Capital Management's KYMR Position: Q2 2024 in Review

Graham Capital Management sold out of Kymera Therapeutics (KYMR) in Q2 2024, closing a stake of 7,557 shares — an estimated $304K sold.

Graham Capital Management first reported a position in KYMR in Q1 2022 and held it in 6 quarters. The position peaked at $2.2M in Q3 2022. 157 funds tracked by Wall St. Rank hold KYMR as of Q2 2024.

  • Graham Capital Management reported no remaining Kymera Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Graham Capital Management sold 7,557 Kymera Therapeutics shares in Q2 2024, an estimated $304K.
  • Graham Capital Management first reported a position in Kymera Therapeutics in Q1 2022 and held it in 6 quarters.
  • Graham Capital Management's Kymera Therapeutics position peaked at $2.2M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2024.

Based on Graham Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.